Meropenem Coverage for Staphylococcus aureus

Coverage Spectrum

The Infectious Diseases Society of America recommends meropenem for empiric coverage of methicillin-sensitive Staphylococcus aureus (MSSA) in hospital-acquired pneumonia when MRSA risk factors are absent 1, 2, 3
Meropenem has no reliable activity against methicillin-resistant Staphylococcus aureus (MRSA) 4
When MRSA coverage is required, vancomycin or linezolid must be added to the regimen, as recommended by the Infectious Diseases Society of America 2, 3
European guidelines confirm that for high-risk patients with >25% MRSA prevalence, an agent with MRSA coverage must be added to any carbapenem regimen, including meropenem 5

Meropenem provides adequate staphylococcal coverage for hospital-acquired pneumonia without MRSA risk factors, as recommended by the Infectious Diseases Society of America 1, 2
Meropenem is suitable for complicated intra-abdominal infections, providing adequate staphylococcal coverage as part of empiric therapy 6, 4
Additional MRSA coverage is mandatory for patients with high mortality risk, recent antibiotic exposure, or high MRSA prevalence, as recommended by the Infectious Diseases Society of America 2, 3, 5
For necrotizing soft tissue infections, empiric vancomycin or linezolid should be added to broad-spectrum coverage including meropenem 7

Once MSSA is confirmed by culture, the Infectious Diseases Society of America recommends switching from meropenem to narrower-spectrum agents, such as oxacillin, nafcillin, or cefazolin, to minimize risks of Clostridioides difficile infection, antibiotic resistance, and adverse effects 1

The Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) 2016 guidelines recommend meropenem as an appropriate empiric option for MSSA coverage in hospital‑acquired pneumonia when patients have no risk factors for MRSA and are not at high risk of mortality. 8
Meropenem is listed among the empiric regimens for hospital‑acquired pneumonia that require MSSA coverage, together with piperacillin‑tazobactam, cefepime, levofloxacin, and imipenem. 9

If any MRSA risk factors exist (e.g., recent IV antibiotic use, unit MRSA prevalence > 20 %, or high mortality risk), the IDSA/ATS guidelines advise adding vancomycin or linezolid to a meropenem‑based regimen. 8
For necrotizing soft‑tissue infections, empiric MRSA coverage (vancomycin or linezolid) should be added to the broad‑spectrum regimen that includes meropenem. 10

Meropenem provides reliable MSSA activity in complicated intra‑abdominal infections and delivers complete anaerobic coverage, eliminating the need for additional agents such as metronidazole. 11